Skip to main content

crizotinib (Xalkori®)

 

Status: Excluded due to NICE appraisal

Product meets AWMSG exclusion criteria due to NICE appraisal TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (replaced TA296)

Medicine details

Medicine name crizotinib (Xalkori®)
Formulation 200 mg, 250 mg capsule
Reference number 791
Indication

Treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer

Company Pfizer Ltd
BNF chapter Malignant disease & immunosuppression
Submission type N/A
Status Excluded due to NICE appraisal
Date of issue 21/03/2013
NICE guidance

TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (replaced TA296)

Follow AWTTC: